Modified Sensory Testing in Non-verbal Patients Receiving Novel Intrathecal Therapies for Neurological Disorders

Several neurological disorders may be amenable to treatment with gene-targeting therapies such as antisense oligonucleotides (ASOs) or viral vector-based gene therapy. The US FDA has approved several of these treatments; many others are in clinical trials. Preclinical toxicity studies of ASO candida...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornelissen, Laura, Donado, Carolina, Yu, Timothy W., Berde, Charles B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866183/
https://www.ncbi.nlm.nih.gov/pubmed/35222234
http://dx.doi.org/10.3389/fneur.2022.664710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866183/
https://www.ncbi.nlm.nih.gov/pubmed/35222234
http://dx.doi.org/10.3389/fneur.2022.664710

Ejemplares similares